DUBLIN L2 4, L2
| Name & Role | Position | Tenure | Holdings |
|---|---|---|---|
ANTARES PHARMA, INC. | — | Since Mar 2019 | — |
EMERGENT BIOSOLUTIONS INC. | EVP, Chief Medical Officer | Since May 2020 | — |
TOURMALINE BIO, INC. | — | Since May 2022 | — |
QUINCE THERAPEUTICS, INC. | Chief Medical Officer | Since May 2022 | — |
ACCELERON PHARMA INC | — | Since Jan 2019 | — |
SANGAMO THERAPEUTICS, INC | — | Since Jun 2019 | — |
SKYE BIOSCIENCE, INC. | — | Since Feb 2026 | — |
AURINIA PHARMACEUTICALS INC. | — | Since Aug 2023 | — |
CONTEXT THERAPEUTICS INC. | — | Since Sep 2024 | — |